Promise Pharmacy, LLC, Palm Harbor, FL

Is Promise Pharmacy, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Promise Pharmacy, LLC hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH22007 for PROMISE PHARMACY, LLC, PALM HARBOR, status Clear and PH29090 for PROMISE PHARMACY LLC (dba Promise Pharmacy LLC), PALM HARBOR, status Clear. The Colorado State Board of Pharmacy also lists nonresident license OSP 6869 for Promise Pharmacy, Palm Harbor, FL, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054020703 for PROMISE PHARMACY LLC, PALM HARBOR, FL, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003425 for PROMISE PHARMACY, PALM HARBOR, FL, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0002134 for Promise Pharmacy, LLC, PALM HARBOR, FL, status Active, license A9-0001945 for Promise Pharmacy, LLC, Palm Harbor, FL, status Closed and license A9-0012869 for Promise Pharmacy, LLC, PALM HARBOR, FL, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301013512 for Promise Pharmacy, LLC, Palm Harbor, FL, status Active, as of Nov 10, 2026.

Has Promise Pharmacy, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 29, 2019), 1 warning letter close-out (Jul 27, 2022), 1 state referral letter (Jul 27, 2022) and 1 FMD-145 letter (Jul 27, 2022) for Promise Pharmacy, LLC. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 2 actions: “Obligation(s) Satisfied” dated Sep 22, 2020, case 201806234 on license PH29090 and “Administrative Complaint Filed” dated May 21, 2020, case 201806234 on license PH29090. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Promise Pharmacy, LLC
Location
Palm Harbor, FL
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
1
Latest action on that page
Jul 27, 2022
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 16 observations
State board records
License found: PH22007, Clear; PH29090, Clear

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Promise Pharmacy, LLC, a 503A facility, with 5 dated actions.

Document
Jul 27, 2022State referral letterReferral Letter to the Florida Board of Pharmacy Issued 07/27/2022FDA copy (archived)
Jul 27, 2022FMD-145 letterFMD-145 Letter Issued 07/27/2022Not linked by FDA
Jul 27, 2022Warning letter close-outWarning Letter Close Out Issued 07/27/2022Not linked by FDA
Sep 23, 2021Form 483483 Issued 09/23/2021FDA copy (archived)
Jul 29, 2019Warning letterWarning Letter (07/29/2019)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Promise Pharmacy, LLC, Palm Harbor, FL (FEI number 3013207472), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 23, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30132074721153148
Oct 25, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30132074721069714

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 16 numbered observations in all, across 2 inspections ending Oct 25, 2018 to Oct 25, 2018. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Oct 15, 2018 to Oct 25, 2018: 8 observations

Firm on the cover
Promise Pharmacy, LLC, 31318 Us Highway 19 N, Palm Harbor, FL 34684 -3713
FEI number
3013207472
Establishment type on the cover
Producer of sterile and non-sterile products
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not.

Specifically, on 10/19/18, I observed the following:

An operator blocked first pass HEPA filtered air dming the production of Bremelanotide, Lot 1019018@4, BUD 12/18/18. •

An operator did not move slow and deliberate in the ISO 5 environment when transf ening partiallystoooered vials of Bremelanotide, Lot 1019018@4, BUD 12/18/18, from the compounding table to <Redacted B4>

f

An operator did not wear· a bear·d cover dming the production of HCG 2000ill Injectable, Lot10192018@6, BUD 04/17/18.

Observation 2

The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically, yom firm does not perform a visual examination of finished drug products prior to dispensing and distribution. On 10/16/18, I observed the presence of particulates in multiple bottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2, BUD 12/03/18. <Redacted B4> bottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2 had ah-eady been dispensed and distiibuted.

AM ENDMENT 1

Observation 3

The flow of components, drug product containers, closures and in-process materials though the building is not designed to prevent contamination.

Specifically,

A. The environment in which sterile, non-hazardous drug products are produced does not meet the standards of an ISO 5 environment due to the following:

HEP A filters do not cover the entire room. • • • •

There is no full assessment of the room's pressure differentials .

Smoke studies were not performed throughout the entire room .

There is a non-classified <Redacted B4> from the ISO 8 Prep room to the ISO 5 sterile environment.

B. On 10/19/18, I observed the transfer of partially stoppered Brenelanotide, Lot 10192018@4 from the stainless-steel compounding table to the <Redacted B4> in the ISO 5 sterile, non-hazardous room. I observed the <Redacted B4> is partially located under a light fixture that does not have a HEPA filter.

Observation 4

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

AM ENDMENT 1

Specifically, your fnm dof _n~t pe1form sterility and endotoxin testing on batches of sterile hazardous and non­4hazardous dmg products o >< ~ials/bottles or less. Examples include, but are not limited to:

Ascorbic Acid Injection 450mg/mL Injectable, Lot 07202018@19, BUD 09/03/18

Arginine HCL 200mg/mL Injectable, Lot 02082018@13, BUD 03/25/18

Magnesium Sulfate 500mg/mL Injectable, Lot 08282018@2, BUD 10/12/18

Observation 5

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically,

A. Your firm does not perform potency testing on all batches of sterile drug products prior to release and distribution. Examples include, but are not limited to:

Ascorbic Acid 450mg/mL Injectable, Lot 07062018@2, BUD 08/20/18

Magnesium Sulfate 500mg/mL, Lot 08282018@2, BUD 10/12/18

Dexpanthenol USP 250mg/mL, Lot 02082018@15, BUD 03/25/18

Sermorelin GHRP 6 GHRP 2 PF 6mg/3mg/3mg Injectable, Lot 08302018@13, BUD 02/26/19

B. Your fnm released and distributed <Redacted B4> vials of Bremelanotide (PT141) 20mg Injectable Lot 05312018@4, BUD 07/30/18, with super-potent results for Bremelanotide of 114.3% (specification <Redacted B4>.

C. Your firm released and distiibuted vials of Sermorelin GHRP 6 GHRP 2 PF 6mg/3mg/3mg Injectable, Lot 05312018@3, BUD 11/27/18, with super-potent results for GHRP-2 of 112.4% (specifications 90-110%) and GHRP-6 of 113.8% GHRP-6 (specifications[(t>) (Ll-) I

4 D. ...

Read the full 483 (PDF on fda.gov)

Observation 6

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm lacks written procedures for a continuous stability program; and your firm does not perform stability testing for sterility or endotoxin on sterile hazardous and non-hazardous diug products. For example, Stability/BUD study for Ascorbic Acid 450mg/mL Injectable, Lot 05012018@42 to extend the BUD from 45 days to 90 days did not have sterility or endotoxin testing at the final test time point dated 07/27/18.

Observation 7

Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, the validation of your fnm's <Redacted B4> and <Redacted B4> lack temperature mapping to ensure the required internal temperatures are reached and maintained throughout batch for the required runtime.

Observation 8

Your firm released drug produt in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically,

AM ENDMENT1

A. Quality Related Event Report (QRE) dated 06/26/18: A complaint was received for Rx# <Redacted B6> for particles floating in the injectable a few days after reconstitution for AOD 9604 PF 6mg Injection, Lot 06182018@3, BUD 09/16/18. Your firm performed an investigation confnming the presence of particles for multiple lots of AOD 9604 PF 6mg Injection. The probable root cause was identified as a problem with the AOD powder, Lot <Redacted B4> used to produce the batches. Your firm failed to perform a risk assessment assessing the impact and to take correction actions, if indicated, regarding the following AOD injectable batches using AOD powder, Lot <Redacted B4> that were released and distributed 01162018@14, 03192018@2, 05142018@4, and 06182018@3

B. QRE dated 02/09/18: On 02/09/18, your firm identified a sterility failure for Thymosin B4 PF 15MG Injectable, Lot 01312018@1, BUD 05/01/18. ...

Read the full 483 (PDF on fda.gov)

Inspection Oct 15, 2018 to Oct 25, 2018: 8 observations

Firm on the cover
Promise Pharmacy, LLC, 31818 us Highway 19 N, Palm Harbor, FL 34684 -3713
FEI number
3013207472
Establishment type on the cover
Producer of sterile and non-sterile products
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drng products purporting to be sterile are not.

Specifically, on 10/19/18, I observed the following:

An operator blocked first pass HEP A filtered air during the production of Bremelanotide, Lot 1019018@4, BUD 12/18/18.

An operator did not move slow and deliberate in the ISO 5 environment when transfening partially stopped vials of Bremelanotide, Lot 1019018@4, BUD 12/18/18, from the compounding table to <Redacted B4>

An operator did not wear a beard cover during the production of HCG 2000TIJ Injectable, Lot 10192018@6, BUD 04/17/18.

Observation 2

The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically, your firm does not perform a visual examination of fmished drug products prior to dispensing and distiibution. On 10/16/18, I observed the presence of particulates in multiple bottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2, BUD 12/03/ 18.fl ibottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2 had already been dispensed and distiibuted.

Observation 3

The flow of components, drug product containers, closures and in-process materials though the building is not designed to prevent contamination.

Specifically,

A. The environment in which sterile, non-hazardous drug products are produced does not meet the standards of an ISO 5 enviromnent due to the following:

HEPA filters do not cover the entire room. • • • •

HEPA filters do not cover the entire room. There is no full asessment of the room's pressure differentials. Smoke studies were not performed throughout the entire room .

There is a non-classified <Redacted B4> from the ISO 8 Prep room to the ISO 5 sterile environment.

B. On 10/18/18, I observed the transfer of partially stoppered Bremelanotide, Lot 10192018@4, from the stainless-steel compounding table to the <Redacted B4> in the ISO 5 stelile, non-hazardous room. I observed the <Redacted B4> is partially located under a light fixture that does not have a HEPA filter.

Observation 4

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Ascorbic Acid Injection 450mg/mL Injectable, Lot 07202018@19, BUD 09/03/18

Arginine HCL 200mg/mL Injectable, Lot 02082018@13, BUD 03/25/18

Magnesium Sulfate 500mg/mL Injectable, Lot 08282018@2, BUD 10/12/18

Observation 5

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically,

A. Your firm does not perform potency testing on all batches of sterile drug products prior to release and distribution . Examples include, but are not limited to:

Ascorbic Acid 450mg/mL Injectable, Lot 07062018@2, BUD 08/20/18

Magnesium Sulfate 500mg/mL, Lot 08282018@2, BUD 10/12/18

Dexpanthenol USP 250mg/mL, Lot 02082018@15, BUD 03/25/18

Semorelin GHRP 6 GHRP 2 PF 6mg/3mg/3mg Injectable, Lot 08302018@13, BUD 02/26/19

B. Your firm released and distributed <Redacted B4> vials of Bremelanotide (PTl41) 20mg Injectable, Lot 05312018@4, BUD 07/30/18, with super-potent results for Bremelanotide of 114.3% (specifications <Redacted B4>

C. Your firm released and distiibuted <Reda cte d B4> vials of S en norel in GH RP 6 GHRP 2 PF 6mg/3mg/3 mg I njectable, L ot 0 5312018@3, BUD 11/27/18, wit h super- pote nt resu lts for GH RP-2 of 112.4% (sp ec i fi cations <Redacted B4> , land GHRP-6 of 113.8% GH R P -6 (specifications <Redacted B4>

D. ...

Read the full 483 (PDF on fda.gov)

Observation 6

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your finn lacks written procedures for a continuous stability program; and your film does not perfonn stability testing for sterility or endotoxin on sterile hazardous and non-hazardous drng products. For example, Stability/BUD study for Ascorbic Acid 450mg/mL Injectable, Lot 05012018@42 to extend the BUD from 45 days to 90 days did not have stetility or endotoxin testing at the final test time point dated 07/27/18.

Observation 7

Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, the validation of your firm's <Redacted B4> and <Redacted B4> lack temperature mapping to ensure the required internal temperatures are reached and maintained throughout batch for the required runtime.

Observation 8

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically,

A. Quality Related Event Rep01t (QRE) dated 06/26/1 8: A complaint was received for Rx# <Redacted B4> for particles floating in the injectable a few days after reconstitution for AOD 9604 PF 6mg Injection, Lot 06182018@3, BUD 09/16/18. Your firm performed an investigation confirming the presence of particles for multiple lots of AOD 9604 PF 6mg Injection. The probable root cause was identified as a problem with the AOD powder, Lot <Redacted B4> used to produce the batches. Your firm failed to perform a risk assessment assessing the impact and to take corrective actions, if indicated, regarding the following AOD injectable batches using AOD powder, Lot <Redacted B4> , lthat were released and distributed: 01162018@14, 03192018@2, 05142018@4, and 06182018@3.QRE dated 02/09/18.

B. On 02/09/18, your firm identified a sterility failure for Thymosin B4 PF l 5MG Injectable, Lot 01312018@1, BUD 05/01/18. ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH22007PharmacyPROMISE PHARMACY, LLCPALM HARBORClear
PH29090PharmacyPROMISE PHARMACY LLC (dba Promise Pharmacy LLC)PALM HARBORClear

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6869OSPPromise PharmacyPalm Harbor, FLActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054020703LICENSED PHARMACYPROMISE PHARMACY LLCPALM HARBOR, FLACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0003425NONRESIDENT PHARMACYPROMISE PHARMACYPALM HARBOR, FLACTIVE (CURRENT)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0002134Non Resident PharmacyPromise Pharmacy, LLCPALM HARBOR, FLActive
A9-0001945Non Resident PharmacyPromise Pharmacy, LLCPalm Harbor, FLClosed
A9-0012869Non Resident PharmacyPromise Pharmacy, LLCPALM HARBOR, FLClosed

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301013512PharmacyPromise Pharmacy, LLCPalm Harbor, FLActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.